Teladoc Health, Inc. (TDOC) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $6.43 (-2.13%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | George Hill | Deutsche Bank | $11.00 | +70.9% |
| Feb 26, 2026 | David Grossman | Stifel Nicolaus | $6.00 | -6.8% |
| Feb 26, 2026 | Stephen Baxter | Wells Fargo | $6.00 | -6.8% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $9.00 | +39.9% |
| Oct 30, 2025 | David Grossman | Stifel Nicolaus | $8.00 | +24.3% |
| Dec 4, 2024 | Jessica Tassan | Piper Sandler | $13.00 | +102.0% |
| Oct 31, 2024 | Daniel Grosslight | Citigroup | $11.00 | +70.9% |
| Oct 30, 2024 | Elizabeth Anderson | Evercore ISI | $9.00 | +39.9% |
| Aug 6, 2024 | Jessica Tassan | Piper Sandler | $10.00 | +55.4% |
| Jun 11, 2024 | Steve Valiquette | Barclays | $20.00 | +210.8% |
| May 31, 2024 | Glen Santangelo | Jefferies | $10.00 | +55.4% |
| May 20, 2024 | Glen Santangelo | Jefferies | $14.00 | +117.6% |
| Apr 5, 2024 | George Hill | Deutsche Bank | $18.00 | +179.7% |
| Apr 12, 2023 | Jeff Garro | Stephens | $25.00 | +288.5% |
| Jul 31, 2022 | Steve Valiquette | Barclays | $42.00 | +552.7% |
| Jul 28, 2022 | Jessica Tassan | Piper Sandler | $40.00 | +521.6% |
| Jul 28, 2022 | Elizabeth Anderson CFA | Evercore ISI | $28.00 | +335.1% |
| May 18, 2022 | Jessica Tassan | Piper Sandler | $42.00 | +552.7% |
| Apr 28, 2022 | Jonathan Yong | Credit Suisse | $35.00 | +443.9% |
| Apr 28, 2022 | Steven Valiquette | Barclays | $45.00 | +599.3% |
Top Analysts Covering TDOC
TDOC vs Sector & Market
| Metric | TDOC | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.25 | 2.42 |
| Analyst Count | 6 | 8 | 18 |
| Target Upside | +42.9% | +16187.2% | +19.5% |
| P/E Ratio | -5.28 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.48B | $2.51B | $2.53B | 19 |
| 2027-03-31 | $610M | $623M | $637M | 8 |
| 2027-06-30 | $620M | $633M | $648M | 8 |
| 2027-09-30 | $621M | $634M | $648M | 11 |
| 2027-12-31 | $634M | $647M | $662M | 8 |
| 2028-03-31 | $621M | $634M | $649M | 10 |
| 2028-06-30 | $631M | $644M | $659M | 7 |
| 2028-09-30 | $638M | $652M | $667M | 14 |
| 2028-12-31 | $642M | $655M | $670M | 9 |
| 2029-12-31 | $2.63B | $2.68B | $2.74B | 5 |
| 2030-12-31 | $2.81B | $2.86B | $2.92B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.09 | $-0.90 | $-0.72 | 11 |
| 2027-03-31 | $-0.24 | $-0.24 | $-0.23 | 2 |
| 2027-06-30 | $-0.19 | $-0.18 | $-0.18 | 2 |
| 2027-09-30 | $-0.17 | $-0.17 | $-0.16 | 2 |
| 2027-12-31 | $-0.13 | $-0.12 | $-0.12 | 2 |
| 2028-03-31 | $-0.27 | $-0.26 | $-0.25 | 3 |
| 2028-06-30 | $-0.21 | $-0.21 | $-0.20 | 3 |
| 2028-09-30 | $-0.16 | $-0.16 | $-0.16 | 3 |
| 2028-12-31 | $-0.15 | $-0.14 | $-0.14 | 3 |
| 2029-12-31 | $-0.16 | $-0.16 | $-0.15 | 2 |
| 2030-12-31 | $0.14 | $0.14 | $0.14 | 5 |
Frequently Asked Questions
What is the analyst consensus for TDOC?
The consensus among 6 analysts covering Teladoc Health, Inc. (TDOC) is Buy with an average price target of $8.00.
What is the highest price target for TDOC?
The highest price target for TDOC is $150.00, set by Steven Halper at Cantor Fitzgerald on 2021-10-28.
What is the lowest price target for TDOC?
The lowest price target for TDOC is $6.00, set by Stephen Baxter at Wells Fargo on 2026-02-26.
How many analysts cover TDOC?
6 analysts have issued ratings for Teladoc Health, Inc. in the past 12 months.
Is TDOC a buy or sell right now?
Based on 6 analyst ratings, TDOC has a consensus rating of Buy (2.50/5) with a +42.9% upside to the consensus target of $8.00.
What are the earnings estimates for TDOC?
Analysts estimate TDOC will report EPS of $-0.90 for the period ending 2026-12-31, with revenue estimated at $2.51B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.